PEDIATRICS Vol. 44 No. 5 November 1969, pp. 685-694
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sullivan, M. P.
Right arrow Articles by Thurman, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sullivan, M. P.
Right arrow Articles by Thurman, W. G.

EVALUATION OF VINCRISTINE SULFATE AND CYCLOPHOSPHAMIDE CHEMOTHERAPY FOR METASTATIC NEUROBLASTOMA

Margaret P. Sullivan M.D.1, Audrey H. Nora M.D.1, Panja Kulapongs M.D.1, Daniel M. Lane M.D.1, Joan Windmiller M.D.1, and William G. Thurman M.D.1

1 Pediatric Division, The Southwest Cancer Chemotherapy Study Group

Among 18 evaluated children with metastatic neuroblastoma who were treated with vincristine sulfate by the Pediatric Division, Southwest Cancer Chemotherapy Study Group, the overall response rate was only 28%. A cyclic regimen using vincristine sulfate and cyclophosphamide alternately weekly produced a response rate of 38% among 21 children. The median duration of remission in each of the treatment groups was 3 months. Previous reports of a high degree of effectiveness for the cyclic regimen could not be confirmed. The presence of definite antitumor effect, however, should encourage the further exploration of the potential of chemotherapeutic regimens as adjuvants to surgery and radiation and as prophylactic therapy for children in whom the disease has not yet become metastatic.

Submitted on March 3, 1969
Accepted on May 9, 1969